FINWIRES · TerminalLIVE
FINWIRES

European Equities Traded in the US as American Depositary Receipts Sharply Higher in Friday Trading

-- European equities traded in the US as American depositary receipts were climbing higher late Friday morning, rising 1.06% to 1,840.68 on the S&P Europe Select ADR Index, which has gained 1.42% for the week.

From continental Europe, the gainers were led by lender Banco Santander (SAN) and software firm SAP (SAP), which advanced 5.3% and 4.2%, respectively. They were followed by healthcare tech company Royal Philips (PHG) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which increased 4.1% each.

The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which dropped 9% and 7.4%, respectively. They were followed by telecommunications company Ericsson (ERIC) and medical device maker EDAP TMS (EDAP), which lost 6.2% and 3.6%, respectively.

The gainers from the UK were led by cruise line operator Carnival (CUK) and biopharmaceutical company NuCana (NCNA), which rose 9.3% and 7.1%, respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and lender Barclays (BCS), which were up 4.7% and 4.6%, respectively.

The decliners from the UK and Ireland were led by oil and gas companies BP (BP) and Shell (SHEL), which fell 8.1% and 5.2%, respectively. They were followed by telecommunications operator Vodafone Group (VOD) and biotech firm Trinity Biotech (TRIB), which were down 2.7% and 2.6%, respectively.

相关文章

Australia

再生元公司称,FDA已加速批准其治疗遗传性听力损失的疗法

再生元公司(Regeneron,股票代码:REGN)周四宣布,美国食品药品监督管理局(FDA)已加速批准其治疗OTOF基因相关听力损失的药物Otarmeni用于治疗儿童和成人患者。 根据一份声明,FDA的批准基于正在进行的Chord试验。该试验显示,20名受试者中有16名在纯音测听评估中听力有所改善,其中14名表现出听觉脑干反应。 再生元公司表示,Otarmeni的持续批准可能取决于Chord试验验证性部分中临床获益的验证和描述。 该公司表示,将为美国符合临床条件的患者免费提供Otarmeni。 该公司股价周四上涨2%。Price: $761.47, Change: $+14.89, Percent Change: +1.99%

$REGN
Sectors

行业动态:医疗保健

周四下午,医疗保健类股下跌,纽约证券交易所医疗保健指数下跌0.5%,道富医疗保健精选行业SPDR ETF (XLV)下跌0.7%。 iShares生物技术ETF (IBB)下跌1.9%。 公司新闻方面,赛默飞世尔科技(TMO)周四上调了全年业绩预期,原因是其第一季度业绩强于预期,尽管内生增长低于分析师预期。该公司股价下跌10.9%。

$TMO
Research

美国银行称,德州仪器将受益于工业复苏和数据中心需求增长。

美国银行周四发布的一份报告指出,德州仪器 (TXN) 有望受益于工业复苏,尤其是在航空航天/国防、数据中心需求以及其美国本土制造业务带来的收益增长。 该券商还表示,随着德州仪器逐步摆脱大规模资本支出周期,其自由现金流有望更加强劲。报告还指出,德州仪器能够利用过去三年在美国晶圆厂的巨额资本支出,在“资源受限”的芯片市场中抢占市场份额。 美国银行还表示,看好德州仪器在直流电源领域的定位,该公司“在机架级产品中占据主导地位,并且随着架构向更高电压/更高功率密度系统发展,其专用插座业务也呈现增长势头”。 然而,美国银行指出,持续的地缘政治动荡仍然是整个行业面临的风险,但补充说,德州仪器历来具有相对更强的防御性。 美国银行将该股评级从“中性”上调至“买入”,并将目标价从 235 美元上调至 320 美元。Price: $283.62, Change: $+47.31, Percent Change: +20.02%

$TXN